Microdosing psychedelics such as psilocybin could have therapeutic benefits for disorders such as ADHD and anxiety, but more double-blind research is needed to differentiate the effects from a placebo. However, there may be a potential overlap between therapeutic use and positive psychology in terms of improving mood and focus.
MDMA may have potential as an empathogen for increasing connection and awareness, but caution is advised for individuals under 25 years old or those who struggle with mental health disorders.
The potential cumulative negative effects of microdosing psychedelics through serotonin 5-HT2B receptor or other mechanisms require careful consideration for physical and psychological safety in the context of research, but there is low concern for toxicity or cardiotoxicity with therapeutic usage of psychedelics a few times in a lifetime.
The speaker discusses their human research with Schedule 1 and 2 drugs, such as psilocybin, methamphetamine, and cocaine, and explains the regulations and lack of restrictions for certain drugs and caffeine products.
The impact of trazodone on neurotransmitter levels varies depending on the specific neurotransmitter. Trazodone primarily affects histamine levels while also having a lesser impact on noradrenaline and serotonin levels.